Advanced Therapies Regulation

ReNeuron Group plc
25 April 2007



ReNeuron welcomes European Parliament support for Advanced Therapies Regulation


Guildford, UK, 25 April 2007: ReNeuron Group plc (LSE: RENE.L) welcomes today's
vote by the European Parliament to create a regulatory framework and single
European marketing authorisation for gene therapy, cell therapy and tissue
engineered products. MEPs voted in favour of a compromise package of amendments
and Parliament rejected all ethical amendments banning products derived from
human embryonic stem cells from the scope of the Regulation.   These amendments
significantly increase the possibility of early adoption of the Regulation.  The
Regulation will harmonise patient access to innovative treatments in Europe by
removing the hurdles created by the many differing regulatory systems across the
Continent.


Michael Hunt, Chief Executive Officer of ReNeuron, said:

'Today's vote is very significant for ReNeuron and all those involved in
developing advanced and innovative therapies for patients in Europe and
elsewhere.  A significant obstacle in ensuring access to these treatments across
Europe has been removed, making possible the establishment of a workable
regulatory system which will assess the efficacy and safety of these therapies
in a consistent manner.  This can serve only to benefit the patients in need of
these treatments as well as those working hard to provide them.'


Enquiries:

ReNeuron
Michael Hunt, Chief Executive Officer            Tel: [phone]
Dr John Sinden, Chief Scientific Officer

Financial Dynamics
David Yates                                      Tel: [phone]
Nicola Daley


Notes to Editors

ReNeuron is a leading, UK-based stem cell therapy business. It is applying its
novel stem cell platform technologies in the development of ground-breaking stem
cell therapies to serve significant and unmet or poorly-met clinical needs.

ReNeuron has used its c-mycER technology to generate genetically stable neural
stem cell lines. This technology platform has multi-national patent protection
and is fully regulated by means of a chemically-induced safety switch. Cell
growth can therefore be completely arrested prior to in vivo implantation.

ReNeuron has filed for approval to commence initial clinical studies in the US
with its lead ReN001 stem cell therapy for chronic stroke disability.  This
represents the world's first such filing concerning a neural stem cell treatment
for a major neurological disorder.  ReNeuron has also generated pre-clinical
efficacy data with its ReN005 stem cell therapy for Huntington's disease, a
genetic and fatal neurodegenerative disorder that affects around 1 in 10,000
people.  This programme is in pre-clinical development.  In addition to its
stroke and Huntington's disease programmes, ReNeuron is developing stem cell
therapies for Parkinson's disease, Type 1 diabetes and diseases of the retina.

ReNeuron has also leveraged its stem cell technologies into non-therapeutic
areas - its ReNcell(TM) range of cell lines for use in research and in drug
discovery applications in the pharmaceutical industry.  ReNeuron's ReNcell(TM) 
CX and ReNcell(TM) VM neural cell lines are marketed worldwide under license by
Millipore Corporation.

ReNeuron's shares are traded on the London AIM market under the symbol RENE.L.

Further information on ReNeuron and its products can be found at
www.reneuron.com.

Data sources: UK Stroke Association; American Stroke Association.

This announcement contains forward-looking statements with respect to the
financial condition, results of operations and business achievements/performance
of ReNeuron and certain of the plans and objectives of management of ReNeuron
with respect thereto. These statements may generally, but not always, be
identified by the use of words such as 'should', 'expects', 'estimates',
'believes' or similar expressions. This announcement also contains
forward-looking statements attributed to certain third parties relating to their
estimates regarding the growth of markets and demand for products. By their
nature, forward-looking statements involve risk and uncertainty because they
reflect ReNeuron's current expectations and assumptions as to future events and
circumstances that may not prove accurate. A number of factors could cause
ReNeuron's actual financial condition, results of operations and business
achievements/performance to differ materially from the estimates made or implied
in such forward-looking statements and, accordingly, reliance should not be
placed on such statements.

The terms 'ReNeuron', 'the Company' or 'the Group' used in this statement refer
to ReNeuron Group plc and/or its subsidiary undertakings, depending on the
context.



                      This information is provided by RNS
            The company news service from the London Stock Exchange